我們已在上線！進一步了解

VOGX

Vogenx Inc

VOGX

市值 US$2.16億

14.53 USD

-1.52

9.47%

收盤時已更新 10月16日下午4:00 EDT

1天

-9.47%

5天

-19.81%

1個月

-56.48%

3個月

11.77%

6個月

11.77%

今年迄今

11.77%

1年

11.77%

5年

11.77%

10年

11.77%

關於： Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

員工： 5

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery RALEIGH, NC / ACCESS Newswire / October 15, 2026 / Vogenx, Inc. (NASDAQ:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the initiation of EMERGE (VGX-001-013), its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). There are currently no therapeutics approved by the U.S. Food and Drug Administration for the treatment of PBH.

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer

Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial readiness as the Company advances mizagliflozin following its August 2026 initial public offering RALEIGH, NC / ACCESS Newswire / October 9, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that Richard "Rich" Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026. Concurrent with his joining the management team, Mr.

Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer

Vogenx Appoints Ken Toombs to Board of Directors

Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company scales operations following its August 2026 initial public offering RALEIGH, NC / ACCESS Newswire / September 22, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee.

Vogenx Appoints Ken Toombs to Board of Directors

Primary Markets Group August IPO Update

August's seven U.S. IPOs matched the prior month's deal count, while aggregate proceeds declined modestly. The month saw $1.8 billion in total proceeds compared to the $3.0 billion raised in July and the $2.9 billion raised across seven IPOs in August 2025. Issuance was dominated by the healthcare sector, which priced five deals and accounted for over $1.4 billion of the total proceeds raised.

Primary Markets Group August IPO Update

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering of Vogenx, Inc. (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism. The offering consisted of 6,250,000 shares of Vogenx common stock at a public offering price of $13.00 per share, at the high end of the proposed range.

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

查看新聞排名

價格圖表採用Lightweight Charts™實作